Publication:
Cardiac complications in beta-thalassemia: From mice to men

dc.contributor.authorSirinart Kumfuen_US
dc.contributor.authorSuthat Fucharoenen_US
dc.contributor.authorSiriporn C. Chattipakornen_US
dc.contributor.authorNipon Chattipakornen_US
dc.contributor.otherChiang Mai Universityen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-21T06:47:56Z
dc.date.accessioned2019-03-14T08:02:53Z
dc.date.available2018-12-21T06:47:56Z
dc.date.available2019-03-14T08:02:53Z
dc.date.issued2017-06-01en_US
dc.description.abstract© 2017, © 2017 by the Society for Experimental Biology and Medicine. Beta-thalassemia is an inherited hemoglobin disorder caused by reduced or absent synthesis of the beta globin chains of hemoglobin. This results in variable outcomes ranging from clinically asymptomatic to severe anemia, which then typically requires regular blood transfusion. These regular blood transfusions can result in an iron overload condition. The iron overload condition can lead to iron accumulation in various organs, especially in the heart, leading to iron overload cardiomyopathy, which is the major cause of mortality in patients with thalassemia. In the past decades, there is no doubt that the use of β-thalassemic mice as a study model to investigate the pathophysiology of iron overload cardiomyopathy and the role of various pharmacological interventions, has shed some light in understanding this serious complication and in improving the associated cardiac dysfunction. In this review, the effects that iron overload has on the hearts of β-thalassemic mice under conditions of iron overload as well as the efficacy of pharmacological interventions to combat these adverse effects on the heart are reviewed and discussed. The in-depth understanding of biomolecular alterations in the heart of these iron overload thalassemic mice will help give guidance for more effective therapeutic approaches in the near future. Impact statement: Iron overload cardiomyopathy is a major cause of morbidity and mortality in patients with thalassemia. Since investigation of iron overload cardiomyopathy in thalassemia patients has many limitations, a search for an animal model for this condition has been ongoing for decades. In the past decades, there is no doubt that the use of β-thalassemic mice as a study model to investigate the pathophysiology of iron overload cardiomyopathy and the role of various pharmacological interventions, has shed some light in understanding this serious complication and in improving the associated cardiac dysfunction. In this review, the effects of iron overload on the hearts of β-thalassemic mice under conditions of iron overload as well as the efficacy of pharmacological interventions to combat these adverse effects on the heart are reviewed and discussed.en_US
dc.identifier.citationExperimental Biology and Medicine. Vol.242, No.11 (2017), 1126-1135en_US
dc.identifier.doi10.1177/1535370217708977en_US
dc.identifier.issn15353699en_US
dc.identifier.issn15353702en_US
dc.identifier.other2-s2.0-85020291584en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/41869
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85020291584&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleCardiac complications in beta-thalassemia: From mice to menen_US
dc.typeReviewen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85020291584&origin=inwarden_US

Files

Collections